Meiragtx Holdings Plc Quick Ratio (MGTX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Meiragtx Holdings Plc  (NASDAQ: MGTX)

Meiragtx Holdings Plc's Quick Ratio

MGTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Meiragtx Holdings Plc's Cash & cash equivalent grew by 100.12 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Meiragtx Holdings Plc's Quick Ratio to 2.46, Quick Ratio remained below Meiragtx Holdings Plc average.

Within Biotechnology & Pharmaceuticals industry 84 other companies have achieved higher Quick Ratio than Meiragtx Holdings Plc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 2863, from total ranking in the first quarter 2026 at 3177.

Explain Quick Ratio?
How much Cash & cash equivalents MGTX´s has?
What are MGTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MGTX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 8.72 % 236.3 % 101.63 % 157.37 % 13.68 %
Y / Y Cash & cash equivalent Change 345.08 % 7.54 % -36.4 % -87.92 % -67.83 %
Quick Ratio MRQ 2.46 0.41 0.54 0.1 0.6
MGTX's Total Ranking # 2863 # 3177 # 4514 # 2920 # 2083
Seq. Current Liabilities Change -67.01 % 43.71 % -19.86 % 186.18 % 2.03 %
Seq. Cash & cash equivalent Change 100.12 % 8.51 % 344.25 % -53.86 % -51.65 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 85
Healthcare Sector # 450
Overall Market # 1257


Quick Ratio Statistics
High Average Low
11.62 3.04 0.1
(Jun 30 2018)   (Sep 30 2025)




Financial Statements
Meiragtx Holdings Plc's Current Liabilities $ 58 Millions Visit MGTX's Balance sheet
Meiragtx Holdings Plc's Cash & cash equivalent $ 143 Millions Visit MGTX's Balance sheet
Source of MGTX's Sales Visit MGTX's Sales by Geography


Cumulative Meiragtx Holdings Plc's Quick Ratio

MGTX's Quick Ratio for the trailling 12 Months

MGTX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 125.52 % 130 % 77.55 % 43.23 % -0.51 %
Y / Y Cash & cash equivalent TTM Growth -9.15 % -53.06 % -59.74 % -53.95 % -21.08 %
Quick Ratio TTM 0.58 0.37 0.47 0.68 1.44
Total Ranking TTM # 2310 # 2387 # 1459 # 838 # 691
Seq. Current Liabilities TTM Growth 0.92 % 32.46 % 19.33 % 41.37 % 2.93 %
Seq. Cash & cash equivalent TTM Growth 60.17 % 2.8 % -17.37 % -33.22 % -17.25 %

Quick ratio ranking by company, industry and sector >> Back to MGTX Financial Strength Comparisons >> Go to Compare MGTX Quick Ratio to its Competitors

On the trailing twelve months basis MGTX Cash & cash equivalent more than doubled by 345.08 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Meiragtx Holdings Plc's Quick Ratio to 0.58, Quick Ratio remained below MGTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Meiragtx Holdings Plc. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2920.

Explain Quick Ratio?
How much Cash & cash equivalents MGTX´s has?
What are MGTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 143
Healthcare Sector # 901
Within the Market # 2863


trailing twelve months Quick Ratio Statistics
High Average Low
7.37 2.72 0.37
(Mar 31 2019)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Fennec Pharmaceuticals Inc   6.66 $ 82.498  Millions$ 12.394  Millions
Krystal Biotech Inc   6.64 $ 845.600  Millions$ 127.397  Millions
Caribou Biosciences Inc   6.33 $ 113.800  Millions$ 17.974  Millions
Cognition Therapeutics inc   6.24 $ 34.012  Millions$ 5.450  Millions
C4 Therapeutics Inc   6.24 $ 300.854  Millions$ 48.247  Millions
Repligen Corp  5.94 $ 810.449  Millions$ 136.403  Millions
Cabaletta Bio Inc   5.64 $ 225.101  Millions$ 39.910  Millions
Revolution Medicines Inc   5.54 $ 3,937.969  Millions$ 710.589  Millions
Humacyte Inc   5.35 $ 79.903  Millions$ 14.948  Millions
Invivyd Inc   5.16 $ 160.080  Millions$ 31.028  Millions
Lineage Cell Therapeutics Inc   5.13 $ 50.855  Millions$ 9.914  Millions
Alector Inc   5.05 $ 172.798  Millions$ 34.236  Millions
Atyr Pharma Inc   5.04 $ 57.418  Millions$ 11.396  Millions
Vericel Corporation  5.04 $ 264.531  Millions$ 52.532  Millions
Inhibrx Biosciences Inc   4.75 $ 133.344  Millions$ 28.064  Millions
Replimune Group Inc   4.57 $ 195.328  Millions$ 42.767  Millions
Recursion Pharmaceuticals Inc   4.55 $ 545.683  Millions$ 119.886  Millions
Prime Medicine Inc   4.50 $ 142.720  Millions$ 31.692  Millions
Immunitybio inc   4.50 $ 357.371  Millions$ 79.392  Millions
Dbv Technologies S a   4.37 $ 174.900  Millions$ 40.000  Millions
Metagenomi Therapeutics Inc   4.37 $ 120.700  Millions$ 27.632  Millions
Alpha Cognition Inc.  4.37 $ 41.443  Millions$ 9.493  Millions
Intensity Therapeutics Inc   4.23 $ 9.500  Millions$ 2.245  Millions
Ginkgo Bioworks Holdings Inc   4.15 $ 302.163  Millions$ 72.740  Millions
Dyadic International Inc   4.13 $ 16.047  Millions$ 3.883  Millions
Tenaya Therapeutics Inc   4.11 $ 78.100  Millions$ 19.021  Millions
Vir Biotechnology Inc   4.08 $ 530.522  Millions$ 130.177  Millions
Adaptive Biotechnologies Corporation  3.92 $ 344.255  Millions$ 87.712  Millions
Immunocore Holdings Plc  3.74 $ 880.211  Millions$ 235.198  Millions
Entera Bio Ltd   3.50 $ 11.309  Millions$ 3.235  Millions

Date modified: 2026-09-12T06:23:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.